Business
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund
Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes Topline data from CATT1 Phase 3 trial on track for second half 2026 HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adju
About this update from Vtv Therapeutics Inc.
[{"type":"image","alt":"vTv Therapeutics Inc.","displaySize":"","headline":null,"caption":"vTv Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AM4EHLX89ULuROtlqZ7i2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156}},"lazy":false},{"type":"text","content":"Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes","length":213,"tagName":"p"},{"type":"text","content":"Topline data from CATT1 Phase 3 trial on track for second half 2026","length":67,"tagName":"p"},{"type":"text","content":"HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (“T1D”), today announced that it has entered into a purchase agreement for an $80 million private placement in public equity (“PIPE”) financing with leading healthcare institutional investors and the T1D Fund: A Breakthrough T1D Venture, LLC (“T1D Fund”). The PIPE financing is subject to customary closing conditions and is expected to close on or around September 3, 2025.","length":684,"tagName":"p"},{"type":"text","content":"Investors in the financing include existing investors in the Company: a life sciences-focused institutional investor, Samsara BioCapital, L.P. (“Samsara”), and the T1D Fund. New investors include Trails Edge Capital Partners, and Invus.","length":236,"tagName":"p"},{"type":"text","content":"TD Cowen and Evercore ISI are acting as lead placement agents for the PIPE financing.","length":85,"tagName":"p"},{"type":"text","content":"Pursuant to the terms of the purchase agreement, the Company is selling to the investors units consisting of an aggregate of 682,018 shares of the Company’s Class A Common Stock and pre-funded warrants to purchase 4,561,714 shares of the Company’s Class A Common Stock, wit...